Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study
2
조회
0
다운로드
3
인용
0
참고문헌
초록
Background/Aims: Clevudine is a pyrimidine analogue with potent activity against hepatitis B virus (HBV) replication in vitro. In a previous pivotal phase III clinical study, 24 weeks treatment with clevudine 30 mg has been shown to profoundly suppress HBV replication and normalize serum alanine aminotransferase level. Methods: In this study, we compare the efficacy and safety of clevudine (30 mg daily) versus lamivudine (100 mg daily) for 48 weeks in treatment-naive chronic hepatitis B e antigen (HBeAg) positive patients. Results: Ninety-two chronic HBeAg positive patients were randomized to receive clevudine 30 mg daily or lamivudine 100 mg daily in a 1:1 ratio. The clevudine group demonstrated greater viral suppression at week 48 when compared with the lamivudine group (median reduction: 4.27 vs. 3.17 log10 copies/ml at week 48, p<0.0001). At week 48, serum HBV DNA level was below 300 copies/mL in 73% and 40% in the clevudine and lamivudine groups, respectively (p=0.001). HBeAg seroconversion occurred in 18% of patients in the clevudine group versus 12% in the lamivudine group at week 48. Lamivudine-resistant mutations were detected in 11 (24%) patients in the lamivudine group, who showed viral rebound during lamivudine therapy but no resistance was found in the clevudine group during 48-week treatment period. Conclusions: A 48-week dosing with clevudine 30 mg daily was superior to lamivudine 100 mg daily in suppressing HBV replication, with no emergence of viral breakthrough in patients with HBeAg positive chronic hepatits B.
Abstract
Background/Aims: Clevudine is a pyrimidine analogue with potent activity against hepatitis B virus (HBV) replication in vitro. In a previous pivotal phase III clinical study, 24 weeks treatment with clevudine 30 mg has been shown to profoundly suppress HBV replication and normalize serum alanine aminotransferase level. Methods: In this study, we compare the efficacy and safety of clevudine (30 mg daily) versus lamivudine (100 mg daily) for 48 weeks in treatment-naive chronic hepatitis B e antigen (HBeAg) positive patients. Results: Ninety-two chronic HBeAg positive patients were randomized to receive clevudine 30 mg daily or lamivudine 100 mg daily in a 1:1 ratio. The clevudine group demonstrated greater viral suppression at week 48 when compared with the lamivudine group (median reduction: 4.27 vs. 3.17 log10 copies/ml at week 48, p<0.0001). At week 48, serum HBV DNA level was below 300 copies/mL in 73% and 40% in the clevudine and lamivudine groups, respectively (p=0.001). HBeAg seroconversion occurred in 18% of patients in the clevudine group versus 12% in the lamivudine group at week 48. Lamivudine-resistant mutations were detected in 11 (24%) patients in the lamivudine group, who showed viral rebound during lamivudine therapy but no resistance was found in the clevudine group during 48-week treatment period. Conclusions: A 48-week dosing with clevudine 30 mg daily was superior to lamivudine 100 mg daily in suppressing HBV replication, with no emergence of viral breakthrough in patients with HBeAg positive chronic hepatits B.
참고문헌 (16)
- Zuckerman AJ, "The association of hepatitis B with primary hepatocellular carcinoma", J Infect, 7(1), pp.73~77 (1983)
- Szmuness W, "Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association", Prog Med Virol, 24, pp.40~69 (1978)
- Beasley RP, "Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan", Lancet, 2, pp.1129~1133 (1981)
- Yao JL, "Perinatal transmission of hepatitis B virus infection and vaccination in China", Gut, 38(2), pp.S37~38 (1996)
- Korenman J, "Long-term remission of chronic hepatitis B after alpha- interferon therapy", Ann Intern Med, 114, pp.629~634 (1991)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates; results after 3 years of therapy", Hepatology, 33, pp.1527~1532 (2001)
- Yoo BC, "Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B", Hepatology, 45, pp.1172~1178 (2007)
- Menne S, "Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection", J Virol, 76, pp.5305~5314 (2002)
- Lau GKK, "Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study", Hepatology, 32, pp.394~399 (2000)
- Chayama K, "Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy", Hepatology, 27, pp.1711~1716 (1998)
- "Hepsera-statistical review and evaluation/<"[URL]
- Chang TT, "A Comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Lai CL, "Telbivudine versus lamivudine in patients with chronic hepatitis B", N Engl J Med, 357, pp.2576~2588 (2007)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Seok JI, "Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA", Hepatology, 49, pp.2080~2086 (2009)